Fibroq Index Patients With Liver Cirrhosis Based On The Magnitude Of The Esophageal Varicose Veins
Fibroq Index Patients with Liver Cirrhosis Based on the Magnitude of the Esophageal Varicose Veins
Discussion Category: Master Theses (Clinical Medicine), Education, Journal, Thesis, University, Student, Campus
Additional Information:
Background
Liver cirrhosis is a serious medical condition that affects millions of people worldwide. In Indonesia, bleeding due to esophageal varicose veins as a complication of liver cirrhosis is the main cause of cases of upper digestive tract bleeding, reaching 70.2%. Globally, the incidence of esophageal varicose veins is recorded between 10-30% of all cases of upper digestive tract bleeding. About two thirds of patients with decompensate and third cirrhosis of patients with compensation cirrhosis have experienced esophageal varicose veins during the diagnosis.
Understanding the Risks of Esophageal Varicose Veins
Esophageal varicose veins are a serious complication of liver cirrhosis that can lead to severe bleeding and even death. The condition occurs when the liver is unable to function properly, causing blood to build up in the veins of the esophagus. This can lead to the formation of varicose veins, which are swollen and twisted veins that can rupture and cause bleeding.
The Need for Noninvasive Parameters
Endoscopic examination to assess esophageal varicose veins in cirrhosis patients is known to be expensive and uncomfortable for patients. Therefore, it is very necessary to have a noninvasive parameter as a predictor of the size of the esophageal varicose veins. One serum biomarker that shows the potential as a prediction aid is the Fibroq index, which has been proven to be well correlated with the liver fibrosis stage. This index can be an alternative choice for liver biopsy. Some previous studies also showed the relationship between liver fibrosis, portal hypertension, and esophageal varicose veins.
Objective
This study aims to evaluate the relationship between the size of the esophageal varicose veins and the Fibroq index as a noninvasive parameter in patients with liver cirrhosis.
Method
This research was conducted with a comparative analytic design using the latitude cutting method. The research subject consisted of non-ambulatory and ambulatory patients who were treated at H. Adam Malik Hospital Medan from June 2014 to June 2014, with a diagnosis of liver cirrhosis based on clinical, biochemical, ultrasonography (USG) criteria, and gastroscopy. The fibroq index is calculated for all patients and the results are analyzed.
Results
Of the 80 patients with esophageal varicose veins involved in the study, 53.8% of them were caused by hepatitis B virus (HBV) infections. Most patients are classified as Child Pugh C, while only 16.3% are included in the category of Child Pugh A. The majority of patients have F2 esophageal varicose (42.5%), followed by F1 (37.5%), and F3 (20 %).
The Relationship Between Fibroq Index and Esophageal Varicose Veins
Research shows a significant difference between the fibroq index and the size of the esophageal varicose veins. The results show that the fibroq index is higher in patients with large esophageal varicose veins compared to small varicose veins (5.38 vs 24.46; p = 0,0001). In addition, the Cutoff Value of the FibroQ index above 8.56 has a high prediction value in the diagnosis of large esophageal varicose veins, with a sensitivity of 90%, 90% specificity, positive prediction value of 93.8%, and negative prediction value of 84.4%.
Conclusion
The fibroq index shows a significant relationship with the size of the esophageal varicose veins in liver cirrhosis patients. With a cutoff value above 8.56, the FibroQ index is proven to be a good noninvasive predictor for detecting large esophageal varicose veins. This finding shows the potential of the Fibroq index for use in clinical practice as a diagnosis aid, which can benefit patients who do not want to undergo an invasive and expensive endoscopic procedure.
Implications for Clinical Practice
The results of this study have significant implications for clinical practice. The use of the Fibroq index as a noninvasive predictor of esophageal varicose veins can help clinicians to identify patients who are at high risk of bleeding and require closer monitoring. This can lead to earlier intervention and improved outcomes for patients with liver cirrhosis.
Future Research Directions
Further research is needed to confirm the findings of this study and to explore the potential of the Fibroq index in other clinical settings. Additionally, studies are needed to investigate the relationship between the Fibroq index and other complications of liver cirrhosis, such as portal hypertension and ascites.
Limitations of the Study
This study has several limitations. The sample size was relatively small, and the study was conducted in a single hospital. Additionally, the study only included patients with liver cirrhosis, and the results may not be generalizable to other populations.
Conclusion
In conclusion, this study demonstrates the potential of the Fibroq index as a noninvasive predictor of esophageal varicose veins in patients with liver cirrhosis. The results of this study have significant implications for clinical practice and highlight the need for further research to confirm the findings and explore the potential of the Fibroq index in other clinical settings.
Fibroq Index Patients with Liver Cirrhosis Based on the Magnitude of the Esophageal Varicose Veins: Q&A
Discussion Category: Master Theses (Clinical Medicine), Education, Journal, Thesis, University, Student, Campus
Additional Information:
Q&A: Understanding the Fibroq Index and Esophageal Varicose Veins
Q: What is the Fibroq index and how is it related to liver cirrhosis?
A: The Fibroq index is a serum biomarker that has been proven to be well correlated with the liver fibrosis stage. It can be an alternative choice for liver biopsy and has been shown to be a good noninvasive predictor for detecting large esophageal varicose veins.
Q: What are esophageal varicose veins and how do they occur?
A: Esophageal varicose veins are a complication of liver cirrhosis that occurs when the liver is unable to function properly, causing blood to build up in the veins of the esophagus. This can lead to the formation of varicose veins, which are swollen and twisted veins that can rupture and cause bleeding.
Q: What are the risks associated with esophageal varicose veins?
A: The risks associated with esophageal varicose veins include severe bleeding, which can lead to death if not treated promptly. Additionally, patients with esophageal varicose veins are at increased risk of developing other complications of liver cirrhosis, such as portal hypertension and ascites.
Q: How can the Fibroq index be used in clinical practice?
A: The Fibroq index can be used as a noninvasive predictor of esophageal varicose veins in patients with liver cirrhosis. It can help clinicians to identify patients who are at high risk of bleeding and require closer monitoring. This can lead to earlier intervention and improved outcomes for patients with liver cirrhosis.
Q: What are the limitations of the study?
A: The study has several limitations, including a relatively small sample size and the fact that it was conducted in a single hospital. Additionally, the study only included patients with liver cirrhosis, and the results may not be generalizable to other populations.
Q: What are the implications of the study for future research?
A: The study highlights the need for further research to confirm the findings and explore the potential of the Fibroq index in other clinical settings. Additionally, studies are needed to investigate the relationship between the Fibroq index and other complications of liver cirrhosis, such as portal hypertension and ascites.
Q: What are the potential benefits of using the Fibroq index in clinical practice?
A: The potential benefits of using the Fibroq index in clinical practice include earlier identification of patients at high risk of bleeding, improved outcomes for patients with liver cirrhosis, and reduced healthcare costs associated with invasive procedures.
Q: How can patients with liver cirrhosis reduce their risk of developing esophageal varicose veins?
A: Patients with liver cirrhosis can reduce their risk of developing esophageal varicose veins by following a healthy lifestyle, including a balanced diet, regular exercise, and avoiding alcohol and tobacco. Additionally, patients should work closely with their healthcare provider to manage their liver disease and prevent complications.
Q: What are the next steps for further research on the Fibroq index?
A: The next steps for further research on the Fibroq index include confirming the findings of this study, exploring the potential of the Fibroq index in other clinical settings, and investigating the relationship between the Fibroq index and other complications of liver cirrhosis.